Commercio INCY

Incyte Corp Ltd

-

00:00:00

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naĆÆve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Leggi tutto...

INCY
Specifiche commerciali

Cifre

2

Punto

0.01

Diffusione

floating

Dimensioni del contratto

1

Volume Min

1

Volume massimo

10,000

Volume Step

1

Scambio lungo (punti)

-1.62

Scambio breve (punti)

-0.94
Disponibile su
MT5, TV, cTrader
Ultimo aggiornamento a Novembre 4, 21:09 GMT+3
*Fonte dei dati: Prezzi del conto MT5 Server Prime

INCY
Calendario economico

Non sono stati trovati dati

Cambiamento 1D

3.597%

PerchƩ BlackBull Mercati?

26k+

AttivitĆ  negoziabili

1:500

Leva fino a

Regolamentato

Multiregolamentato

24/7

Assistenza clienti

$0

Nessun deposito minimo

Calcolatore del margine

Calculation Results

Current Price

75.60

Required Margin

Converted Currency

Required Margin

Account Base Currency

Calcolatore di profitti e perdite

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

Calcolatore di swap

Calculation Results

75.60

OpportunitĆ  di trading

Non sono stati trovati dati
Join Now